Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Replimune Group's outlook is bolstered by a significant increase in the probability of approval for its lead candidate, RP1 in combination with Opdivo, which has been raised to 85%, demonstrating strong confidence in its clinical potential. The safety profile of RP1 + Opdivo is favorable, with a reported 12.8% incidence of grade 3 or higher treatment-related adverse events, indicating a manageable risk for patients. The positive results from the IGNYTE trial further support the case for approval, positioning Replimune favorably in the competitive landscape of cancer therapeutics.

Bears say

Replimune Group Inc faces significant challenges in advancing its key product candidate, RP1, due to regulatory and clinical trial setbacks, including the FDA's determination that the IGNYTE trial lacked adequate evidence of effectiveness. Additionally, the company must contend with risks related to its inability to generate compelling efficacy and safety data, potential dilution, and the failure to deliver on the expectations of its early-stage pipeline of oncolytic virus candidates. The complexity and heterogeneity of the patient population, along with inadequate trial design and statistical assumptions, further hinder Replimune's prospects for regulatory approval, contributing to a negative outlook for the stock.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.